Trump announces trade deal with EU following months of negotiations
Jeffrey William Henderson, a director at Becton Dickinson & Co (NYSE:BDX), recently acquired 1,500 shares of the company’s common stock. The purchase, which took place on February 10, 2025, was made at a price of $233.62 per share, totaling approximately $350,430. Following this transaction, Henderson holds a total of 8,015 shares directly. Additionally, there are 15 shares held indirectly by his wife. This transaction highlights Henderson’s continued investment in the medical instruments and apparatus company, based in Franklin Lakes, New Jersey. The company has maintained dividend payments for 55 consecutive years, with a current yield of 1.81%. Analysts maintain a bullish outlook, with a consensus recommendation of "Buy" and potential upside from current levels. For deeper insights into insider trading patterns and comprehensive analysis, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Becton, Dickinson and Company (BD) has disclosed its plan to separate its Biosciences and Diagnostic Solutions business from the rest of the company. The decision is a strategic move to enhance growth-oriented investments for BD and the separated business. The plan is expected to unlock substantial value for stakeholders and position the new BD as a differentiated MedTech leader.
In addition, BD has declared a quarterly dividend and authorized additional share repurchases. The company has repurchased $750 million of its stock in fiscal 2025 and plans to repurchase up to 10 million shares of common stock.
BD also announced that all nominees for its Board of Directors were elected to serve one-year terms in its 2025 Annual Meeting. Moreover, the appointment of Ernst & Young as the independent registered public accounting firm for fiscal 2025 was ratified with a substantial majority.
Activist investor Starboard Value has also acquired a stake in BD, and there are speculations about a potential sale of BD’s life sciences division. Piper Sandler’s analysts have shown support for such a move, suggesting that a spin-off could provide multiple benefits to shareholders.
These are among the recent developments for BD, a global medical technology firm.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.